于海利

[摘要] 目的 探讨瑞舒伐他汀与阿托伐他汀治疗冠心病的临床疗效，为临床治疗提供依据。 方法 选取我院2013年2月～2015年2月收治的冠心病患者138例，随机分为对照组和治疗组，各69例，对照组在常规治疗的基础上应用阿托伐他汀治疗，治疗组在常规治疗的基础上应用瑞舒伐他汀治疗，15 d后观察两组治疗效果和心功能评级。 结果 治疗组总有效率为97.10%，对照组总有效率为81.16%，两组比较差异有统计学意义（P<0.05）；治疗组心功能分级总有效率为95.65%，对照组为78.26%，两组比较差异有统计学意义（P<0.05）。 结论 在常规治疗的基础上应用瑞舒伐他汀治疗效果明显，心功能分级明显提高，值得临床推广应用。

[关键词] 瑞舒伐他汀；阿托伐他汀；冠心病；临床效果

[中图分类号] R972+.6 [文献标识码] A [文章编号] 1674-4721（2015）09（c）-0094-03

Clinical effect comparison of rosuvastatin and atorvastatin in the treatment of coronary heart disease

YU Hai-li

First Department of Internal Medicine，People′s Hospital in Changchun City，Changchun 130051，China

[Abstract] Objective To investigate the clinical efficacy of rosuvastatin and atorvastatin in the treatment of coronary heart disease and provide reference for clinical treatment. Methods 138 patients with coronary heart disease treated in our hospital from February 2013 to February 2015 were selected and randomly divided into control group and treatment group， with 69 patients in each group.The control group was given atorvastatin treatment on the basis of conventional treatment and the treatment group was given rosuvastatin treatment on the basis of conventional treatment.The treatment effects and cardiac function grading between two groups 15 days later was observed respectively. Results The total effective rate of treatment group was 97.10% and that of control group was 81.16%，with statistical difference（P<0.05）.Regarding to the cardiac function grading，the total effective rate of treatment group was 95.65% and that of control group was 78.26%，with statistical difference（P<0.05）. Conclusion The application of rosuvastatin on the basis of conventional treatment shows obvious effect and improves the cardiac function grading，which is worthy of clinical promotion and application.

[Key words] Rosuvastatin；Atorvastatin；Coronary heart disease；Clinical effec

冠状动脉性心脏病（coronary artery heart disease，CHD）简称冠心病，是一种最常见的心脏病，是指因冠状动脉狭窄、供血不足而引起的心肌障碍和（或）器质性病变，又称缺血性心肌病（IHD）[1-3]。CHD是多种冠状动脉病的结果，但冠状动脉粥样硬化占冠状动脉性心脏病的绝大多数（95%～99%）。症状表现为胸腔中央发生一种压榨性的疼痛，并可迁延至颈、颔、手臂、后背及胃部，并伴有眩晕、气促、出汗、寒战、恶心及昏厥等。严重者可因心力衰竭死亡[4-7]。如不能及时给予合理的治疗，不但延误治疗时机，加重病情，而且会给患者的精神和身体带来极大的痛苦[8-11]。我院在冠心病常规治疗的基础上应用瑞舒伐他汀与阿托伐他汀治疗，对比分析其治疗效果。

1 资料与方法

1.1 一般资料

选取2013年2月～2015年2月我院收治的CHD患者138例，随机分为两组，其中对照组69例，男36例，女33例，年龄39～75岁，平均57岁。治疗组69例，男39例，女30例；年龄37～72岁，平均54.5岁。两组在年龄、性别、病情等方面比较，差异无统计学意义（P>0.05），具有可比性。……